Schrieber L
Sydney University Department of Rheumatology, Royal North Shore Hospital, St. Leonards, NSW, Australia.
Agents Actions Suppl. 1988;24:254-64. doi: 10.1007/978-3-0348-9160-8_23.
A new era is emerging in the therapy of rheumatic disease involving the use of biologically based immunomodulators. Cytokines, such as the interleukins and interferons, are proteins produced by activated lymphoid cells which can now be synthesised by genetic engineering techniques. These agents have already been used to correct "immune deficiencies" in patients with neoplastic and inflammatory disease e.g. gamma-interferon in rheumatoid arthritis (RA). Monoclonal antibodies (mca) targeted against lymphocyte cell surface receptors or against autoantibodies have been successfully applied in human lymphoid malignancies, organ transplantation and in animal models of arthritis. Potential problems in man include the development of allergic reactions to mouse proteins and of antibody resistance. Although in its infancy, immunomodulation represents an exciting approach to the treatment of rheumatic disease.
涉及使用基于生物的免疫调节剂的风湿病治疗新时代正在兴起。细胞因子，如白细胞介素和干扰素，是由活化的淋巴细胞产生的蛋白质，现在可以通过基因工程技术合成。这些药物已被用于纠正肿瘤和炎症性疾病患者的“免疫缺陷”，例如类风湿性关节炎（RA）中的γ-干扰素。针对淋巴细胞细胞表面受体或自身抗体的单克隆抗体（mca）已成功应用于人类淋巴系统恶性肿瘤、器官移植以及关节炎动物模型。在人类中潜在的问题包括对小鼠蛋白产生过敏反应以及产生抗体耐药性。尽管免疫调节尚处于起步阶段，但它是治疗风湿病的一种令人兴奋的方法。
